Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review

Berger, Garrett K.; McBride, Ali; Lawson, Stephanie; Royball, Kelsey; Yun, Seongseok; Gee, Kevin; Riaz, Irbaz Bin; Saleh, Ahlam; Puvvada, Soham D.; Anwer, Faiz

doi:10.1016/j.critrevonc.2016.11.009

Cited by 65 publications

(49 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD30 is a type I transmembrane receptor protein of the TNF receptor superfamily, whose expression in benign tissues is limited to activated and virally infected lymphocytes and certain cells of the thymic medulla . It is expressed on a variety of cancerous cells, particularly Hodgkin and Reed‐Sternberg cells of Hodgkin lymphoma and diffusely in all types of ALCL; however, many other solid and hematologic malignancies have been found to express CD30 at various levels . The function of CD30 in normal cells is poorly understood, as no human disease has been associated with defects in either CD30 or its ligand, CD153 .…”

Section: Discussionmentioning

confidence: 99%

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma

Stack

Levy

2019

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical Message BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresectable BI‐ALCL, which was successfully treated with brentuximab vedotin.

show abstract

Section: Discussionmentioning

confidence: 99%

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma

Stack

Levy

2019

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Camidanlumab Tesirine (ADCT-301) is a pyrrolobenzodiazepine (PBD) Dimer-containing ADC anti-CD25 (the alpha chain of the IL-2 receptor) (35). CD25 is present on the cell surface in B-cell lymphomas such as DLBCL, further than several T-cell lymphoma subtypes (36,37).…”

Section: Anti-cd Mabsmentioning

confidence: 99%

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

et al. 2019

View full text Add to dashboard Cite

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synoptic tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities.

show abstract

“…The published experience of brentuximab vedotin therapy to patients with PTLD is limited to just over ten patients. According to two phase I/II trials and a couple of case reports the response to brentuximab vedotin is favorable for both monomorphic B-and T-cell PTLD [7][8][9][10][11][12][13]. In an ongoing trial, brentuximab vedotin is combined with rituximab as induction and maintenance therapy for lymphomas in immunocompromised patients, including PTLD [4,8].…”

Section: Introductionmentioning

confidence: 99%

CD30 expression and survival in posttransplant lymphoproliferative disorders

et al. 2020

View full text Add to dashboard Cite

Background: Post-transplant lymphoproliferative disorder (PTLD) is a rare but life-threatening complication of transplantation. For refractory and relapsed PTLD new therapies are needed, such as the antibody-drug conjugate brentuximab vedotin that targets CD30. There is limited knowledge of CD30 expression in various subtypes of PTLD and its correlation to clinicopathological features. Therefore, we studied the expression of CD30 in PTLD following solid organ transplantation and correlated CD30 expression to PTLD subtype, Epstein-Barr virus (EBV)-status, intratumoral regulatory T-cells (Tregs), clinical features, and outcome. Methods: We included 50 cases of PTLD from a nationwide study of PTLDs following solid organ transplantation in Sweden. The tumor biopsies were reevaluated, and clinical data were collected. CD30 expression on tumor cells was analyzed by immunohistochemistry with the clone Ber-H2. Thirtyone cases were stained with clone 236 A/E7 for detection of forkhead box protein 3 (FoxP3, a Treg biomarker). Results: The case series consisted of 6% polymorphic, 88% monomorphic, and 6% Hodgkin lymphoma-like PTLDs and 53% of the cases were EBVþ. Overall, 70% (35/50) of the PTLDs were CD30þ (1% CD30þ tumor cells) and 30% (15/50) were CD30-. All polymorphic PTLDs (n ¼ 3) and Hodgkin lymphomas (n ¼ 3), 88% (14/16) of non-germinal center type of diffuse large B-cell lymphoma (DLBCL), and 75% (9/12) of T-cell PTLDs were CD30þ whereas all germinal center-type of DLBCL (n ¼ 5) and Burkitt type PTLD (n ¼ 2) were CD30-. CD30þ PTLD tended to be EBVþ more frequently (p ¼ .07) and occurred earlier posttransplant (2.1 vs. 8.2 years, p ¼ .01) than CD30-PTLD. Type of transplant and localization of the tumor did not differ between the groups except that CNS engagement was more common in CD30-PTLD (p ¼ .02). CD30-status was not associated with presence of intratumoral Tregs or overall survival. Conclusion: Expression of CD30 varied with PTLD subtype. There was no association between CD30 and survival, regardless of subtype.

show abstract

Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review

Cited by 65 publications

References 51 publications

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

CD30 expression and survival in posttransplant lymphoproliferative disorders

Contact Info

Product

Resources

About